The interatrial shunt devices market size has grown rapidly in recent years. It will grow from $2.9 billion in 2025 to $3.2 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising prevalence of heart failure, growing awareness of interatrial shunt therapies, advancements in cardiac imaging, increasing cardiac catheterization procedures, favorable reimbursement policies.
The interatrial shunt devices market size is expected to see rapid growth in the next few years. It will grow to $4.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to technological innovation in shunt devices, expansion of transcatheter delivery methods, aging population with cardiovascular diseases, rising adoption of minimally invasive procedures, increased focus on personalized heart failure management. Major trends in the forecast period include minimally invasive cardiac procedures, personalized heart failure management, device miniaturization, expansion of outpatient cardiac care, advanced hemodynamic monitoring.
The increasing prevalence of heart failure is expected to drive the growth of the interatrial shunt devices market in the coming years. Heart failure is a condition where the heart cannot pump blood effectively, leading to insufficient delivery of oxygen and nutrients to the body’s tissues. The rise in heart failure cases is largely due to the growing incidence of hypertension, which gradually weakens the heart’s pumping ability. Interatrial shunt devices assist in managing heart failure by creating a small opening between the left and right atria, allowing excess pressure from the overloaded left atrium to be relieved by transferring it to the right atrium. This helps reduce pulmonary congestion and alleviates symptoms. For example, in September 2024, the Heart Failure Society of America, a US-based professional organization, reported that approximately 6.7 million Americans aged 20 and older were living with heart failure in 2024. This figure is expected to rise to 11.4 million by 2050. Consequently, the growing prevalence of heart failure is propelling the expansion of the interatrial shunt devices market.
Key players in the interatrial shunt devices market are concentrating on innovative developments, such as first-in-human (FIH) clinical trials to assess the safety and effectiveness of new shunt technologies aimed at lowering left atrial pressure in heart failure patients. A first-in-human clinical trial is the initial phase of testing a new medical device or drug in humans to evaluate safety, tolerability, and early efficacy following successful preclinical research. For instance, in January 2025, Adona Medical Inc., a US-based medical technology company, completed enrollment for its first-in-human (FIH) clinical trial, ATHENS-HF, involving a novel interatrial shunt designed for heart failure treatment. This device is among the first to combine therapeutic shunting with integrated bi-atrial pressure monitoring, offering a more adaptive and personalized method of managing heart failure.
In October 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired V-Wave Ltd. for an undisclosed sum. This acquisition aims to strengthen Johnson & Johnson’s cardiovascular portfolio by adding advanced heart failure therapies and addressing critical unmet needs in the sector. V-Wave Ltd. is an Israel-based medical device firm specializing in innovative interatrial shunt devices.
Major companies operating in the interatrial shunt devices market are Abbott Laboratories, Medtronic plc, Terumo Corporation, Edwards Lifesciences Corporation, Cook Medical, Lepu Medical Technology Beijing Co. Ltd., W. L. Gore & Associates Inc., Venus Medtech Inc., Occlutech Holding AG, Wuhan Vickor Medical Technology Co. Ltd., Corvia Medical Inc., Xeltis BV, Alleviant Medical Inc., Adona Medical Inc., Carag AG, InterShunt Technologies Inc., V-Wave Ltd., MicroPort CardioFlow Group Corp., Medinol Ltd., Lifetech Scientific Corp.
North America was the largest region in the interatrial shunt devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interatrial shunt devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interatrial shunt devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the interatrial shunt devices market by increasing the cost of imported implantable devices and components, affecting supply chains and pricing strategies globally. Surgical delivery and transcatheter delivery devices in North America, Europe, and Asia-Pacific regions are particularly impacted due to high reliance on cross-border trade. While tariffs have raised production costs, they have also encouraged local manufacturing and innovation, promoting regional supply chain diversification and development of cost-effective device solutions.
The interatrial shunt devices market research report is one of a series of new reports that provides interatrial shunt devices market statistics, including interatrial shunt devices industry global market size, regional shares, competitors with a interatrial shunt devices market share, detailed interatrial shunt devices market segments, market trends and opportunities, and any further data you may need to thrive in the interatrial shunt devices industry. This interatrial shunt devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Interatrial shunt devices are implantable medical tools developed to create a controlled passage between the left and right atria of the heart, aiming to lower pressure and alleviate symptoms in heart failure patients. These devices help redirect blood flow from the left atrium to the right atrium, effectively reducing elevated left atrial pressure associated with heart failure.
The primary types of interatrial shunt devices include implantable shunt devices and temporary shunt devices. Implantable shunt devices are designed to create a regulated connection between different body compartments and are typically used to redirect fluid or pressure for therapeutic purposes. These devices can be placed via surgical procedures or transcatheter methods. Common construction materials include nitinol, polyester, and polypropylene. They are primarily used in the treatment of congenital heart defects, heart failure, and stroke prevention, and are employed across various healthcare settings such as hospitals, ambulatory surgical centers, cardiac catheterization labs, and others.
The interatrial shunt devices market consists of sales of catheter-based delivery tools, transseptal access kits, monitoring accessories, and procedure-specific consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The interatrial shunt devices market size is expected to see rapid growth in the next few years. It will grow to $4.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to technological innovation in shunt devices, expansion of transcatheter delivery methods, aging population with cardiovascular diseases, rising adoption of minimally invasive procedures, increased focus on personalized heart failure management. Major trends in the forecast period include minimally invasive cardiac procedures, personalized heart failure management, device miniaturization, expansion of outpatient cardiac care, advanced hemodynamic monitoring.
The increasing prevalence of heart failure is expected to drive the growth of the interatrial shunt devices market in the coming years. Heart failure is a condition where the heart cannot pump blood effectively, leading to insufficient delivery of oxygen and nutrients to the body’s tissues. The rise in heart failure cases is largely due to the growing incidence of hypertension, which gradually weakens the heart’s pumping ability. Interatrial shunt devices assist in managing heart failure by creating a small opening between the left and right atria, allowing excess pressure from the overloaded left atrium to be relieved by transferring it to the right atrium. This helps reduce pulmonary congestion and alleviates symptoms. For example, in September 2024, the Heart Failure Society of America, a US-based professional organization, reported that approximately 6.7 million Americans aged 20 and older were living with heart failure in 2024. This figure is expected to rise to 11.4 million by 2050. Consequently, the growing prevalence of heart failure is propelling the expansion of the interatrial shunt devices market.
Key players in the interatrial shunt devices market are concentrating on innovative developments, such as first-in-human (FIH) clinical trials to assess the safety and effectiveness of new shunt technologies aimed at lowering left atrial pressure in heart failure patients. A first-in-human clinical trial is the initial phase of testing a new medical device or drug in humans to evaluate safety, tolerability, and early efficacy following successful preclinical research. For instance, in January 2025, Adona Medical Inc., a US-based medical technology company, completed enrollment for its first-in-human (FIH) clinical trial, ATHENS-HF, involving a novel interatrial shunt designed for heart failure treatment. This device is among the first to combine therapeutic shunting with integrated bi-atrial pressure monitoring, offering a more adaptive and personalized method of managing heart failure.
In October 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired V-Wave Ltd. for an undisclosed sum. This acquisition aims to strengthen Johnson & Johnson’s cardiovascular portfolio by adding advanced heart failure therapies and addressing critical unmet needs in the sector. V-Wave Ltd. is an Israel-based medical device firm specializing in innovative interatrial shunt devices.
Major companies operating in the interatrial shunt devices market are Abbott Laboratories, Medtronic plc, Terumo Corporation, Edwards Lifesciences Corporation, Cook Medical, Lepu Medical Technology Beijing Co. Ltd., W. L. Gore & Associates Inc., Venus Medtech Inc., Occlutech Holding AG, Wuhan Vickor Medical Technology Co. Ltd., Corvia Medical Inc., Xeltis BV, Alleviant Medical Inc., Adona Medical Inc., Carag AG, InterShunt Technologies Inc., V-Wave Ltd., MicroPort CardioFlow Group Corp., Medinol Ltd., Lifetech Scientific Corp.
North America was the largest region in the interatrial shunt devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interatrial shunt devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interatrial shunt devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the interatrial shunt devices market by increasing the cost of imported implantable devices and components, affecting supply chains and pricing strategies globally. Surgical delivery and transcatheter delivery devices in North America, Europe, and Asia-Pacific regions are particularly impacted due to high reliance on cross-border trade. While tariffs have raised production costs, they have also encouraged local manufacturing and innovation, promoting regional supply chain diversification and development of cost-effective device solutions.
The interatrial shunt devices market research report is one of a series of new reports that provides interatrial shunt devices market statistics, including interatrial shunt devices industry global market size, regional shares, competitors with a interatrial shunt devices market share, detailed interatrial shunt devices market segments, market trends and opportunities, and any further data you may need to thrive in the interatrial shunt devices industry. This interatrial shunt devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Interatrial shunt devices are implantable medical tools developed to create a controlled passage between the left and right atria of the heart, aiming to lower pressure and alleviate symptoms in heart failure patients. These devices help redirect blood flow from the left atrium to the right atrium, effectively reducing elevated left atrial pressure associated with heart failure.
The primary types of interatrial shunt devices include implantable shunt devices and temporary shunt devices. Implantable shunt devices are designed to create a regulated connection between different body compartments and are typically used to redirect fluid or pressure for therapeutic purposes. These devices can be placed via surgical procedures or transcatheter methods. Common construction materials include nitinol, polyester, and polypropylene. They are primarily used in the treatment of congenital heart defects, heart failure, and stroke prevention, and are employed across various healthcare settings such as hospitals, ambulatory surgical centers, cardiac catheterization labs, and others.
The interatrial shunt devices market consists of sales of catheter-based delivery tools, transseptal access kits, monitoring accessories, and procedure-specific consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Interatrial Shunt Devices Market Characteristics
3. Interatrial Shunt Devices Market Supply Chain Analysis
4. Global Interatrial Shunt Devices Market Trends and Strategies
5. Interatrial Shunt Devices Market Analysis of End Use Industries
7. Global Interatrial Shunt Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Interatrial Shunt Devices Total Addressable Market (TAM) Analysis for the Market
9. Interatrial Shunt Devices Market Segmentation
10. Interatrial Shunt Devices Market Regional and Country Analysis
11. Asia-Pacific Interatrial Shunt Devices Market
12. China Interatrial Shunt Devices Market
13. India Interatrial Shunt Devices Market
14. Japan Interatrial Shunt Devices Market
15. Australia Interatrial Shunt Devices Market
16. Indonesia Interatrial Shunt Devices Market
17. South Korea Interatrial Shunt Devices Market
18. Taiwan Interatrial Shunt Devices Market
19. South East Asia Interatrial Shunt Devices Market
20. Western Europe Interatrial Shunt Devices Market
21. UK Interatrial Shunt Devices Market
22. Germany Interatrial Shunt Devices Market
23. France Interatrial Shunt Devices Market
24. Italy Interatrial Shunt Devices Market
25. Spain Interatrial Shunt Devices Market
26. Eastern Europe Interatrial Shunt Devices Market
27. Russia Interatrial Shunt Devices Market
28. North America Interatrial Shunt Devices Market
29. USA Interatrial Shunt Devices Market
30. Canada Interatrial Shunt Devices Market
31. South America Interatrial Shunt Devices Market
32. Brazil Interatrial Shunt Devices Market
33. Middle East Interatrial Shunt Devices Market
34. Africa Interatrial Shunt Devices Market
36. Interatrial Shunt Devices Market Competitive Landscape and Company Profiles
37. Interatrial Shunt Devices Market Other Major and Innovative Companies
40. Interatrial Shunt Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Interatrial Shunt Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses interatrial shunt devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for interatrial shunt devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interatrial shunt devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Device Type: Implantable Shunt Devices; Temporary Shunt Devices2) By Delivery Method: Surgical Delivery; Transcatheter Delivery
3) By Material: Nitinol; Polyester; Polyproplene
4) By Application: Heart Failure With Preserved Ejection Fraction HFpEF; Heart Failure; Left Atrial Pressure Reduction
5) By End-User: Hospitals; Ambulatory Surgical Centers; Cardiac Catheterization Laboratories; Other Users
Subsegments:
1) By Implantable Shunt Devices: Single-Lumen Shunt Devices; Expandable Shunt Devices; Multi-Lumen Shunt Devices2) By Temporary Shunt Devices: Balloon-Assisted Shunt Devices; Percutaneous Temporary Shunt Devices; Catheter-Based Shunt Devices
Companies Mentioned: Abbott Laboratories; Medtronic plc; Terumo Corporation; Edwards Lifesciences Corporation; Cook Medical; Lepu Medical Technology Beijing Co. Ltd.; W. L. Gore & Associates Inc.; Venus Medtech Inc.; Occlutech Holding AG; Wuhan Vickor Medical Technology Co. Ltd.; Corvia Medical Inc.; Xeltis BV; Alleviant Medical Inc.; Adona Medical Inc.; Carag AG; InterShunt Technologies Inc.; V-Wave Ltd.; MicroPort CardioFlow Group Corp.; Medinol Ltd.; Lifetech Scientific Corp.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Interatrial Shunt Devices market report include:- Abbott Laboratories
- Medtronic plc
- Terumo Corporation
- Edwards Lifesciences Corporation
- Cook Medical
- Lepu Medical Technology Beijing Co. Ltd.
- W. L. Gore & Associates Inc.
- Venus Medtech Inc.
- Occlutech Holding AG
- Wuhan Vickor Medical Technology Co. Ltd.
- Corvia Medical Inc.
- Xeltis BV
- Alleviant Medical Inc.
- Adona Medical Inc.
- Carag AG
- InterShunt Technologies Inc.
- V-Wave Ltd.
- MicroPort CardioFlow Group Corp.
- Medinol Ltd.
- Lifetech Scientific Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.2 Billion |
| Forecasted Market Value ( USD | $ 4.71 Billion |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
